Physician profile
Eric R Anger
NPI 1376535096
$2,336.59
in general payments reported to CMS, 2019-2025
25 companies · $85.63 in 2025
The $85.63 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $399 · 2020: $102 · 2021: $187 · 2022: $120 · 2023: $767 · 2024: $675 · 2025: $85.63.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,528.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,528.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $733.86 | 2019-2025 | Vraylar, Ubrelvy, Qulipta |
| Novo Nordisk INC | $242.92 | 2019-2024 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $233.64 | 2019-2024 | Breztri, Farxiga, Bevespi Aerosphere |
| Glaxosmithkline, LLC. | $166.82 | 2019-2025 | Shingrix, Trelegy Ellipta |
| Pfizer INC. | $128.67 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $127.19 | 2023-2024 | Xifaxan |
| Exact Sciences Corporation | $112.47 | 2023-2024 | Cologuard Collection Kit |
| Lilly USA, LLC | $73.69 | 2019-2024 | Mounjaro |
| Mylan Specialty L.P. | $56.67 | 2019-2023 | Yupelri |
| Corcept Therapeutics | $47.49 | 2024 | Korlym |
| Bayer Healthcare Pharmaceuticals INC. | $44.52 | 2022-2023 | |
| Abbott Laboratories | $44.27 | 2021 | |
| Organogenesis INC. | $40.71 | 2024 | |
| Philips North America LLC | $39.73 | 2023-2024 | (Ak6) Vest Therapy |
| Amgen INC. | $34.96 | 2020-2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $34.72 | 2023 | Dexcom G6 Transmitter |
| Novartis Pharmaceuticals Corporation | $29.32 | 2022-2023 | |
| Amarin Pharma, INC. | $26.44 | 2019 | |
| Phathom Pharmaceuticals, INC. | $23.23 | 2023 | Voquezna |
| Janssen Pharmaceuticals, INC | $19.71 | 2021 | |
| Ironshore Pharmaceuticals INC. | $19.48 | 2019 | |
| Merck Sharp & Dohme LLC | $15.96 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $14.73 | 2019 | |
| Shield Therapeutics INC | $12.88 | 2023 | Accrufer |
| Shire North American Group INC | $12.51 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Anger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.